Gene Therapy Drubbings: What Does it Mean for California's $12 Billion Research Effort?
Three companies and big layoffs, missteps and canceled research
The business of gene therapy took a bit of a beating this past week or so, with three, once well-regarded firms laying off employees amid worries about the viability of their potential treatments and their financial outlook.
Their stock prices have been hammered and long-standing, broader questions about the industry have…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.